MabThera, also known as rituximab, is a prescription medicine used to treat non-Hodgkin’s lymphoma (NHL).
- Induction treatment, in combination with chemotherapy.
- Maintenance therapy, as a single treatment for a set number of cycles to help prevent relapse.
How MabThera works
MabThera is a type of treatment called monoclonal antibody therapy, and it works differently to other forms of cancer medicine you may know about or have received.
Antibodies are proteins produced naturally in the body, which specifically recognise and bind to other unique proteins in the body called antigens. Researchers have learned how to engineer and produce antibodies that target specific antigens found on cancer cells. These are known as monoclonal antibodies, and they mimic natural antibodies.
MabThera has been designed to target and attach to the CD20 protein (antigen) found on the surface of mature B lymphocytes, a type of white blood cell. Follicular lymphoma cells are affected B lymphocytes that can be targeted by MabThera.
Once attached to the CD20 protein, MabThera works in two different ways:
1. By helping your own immune system destroy the cancer cells
2. By destroying the cancer cells on its own.
MabThera can either be given as a solution into the veins (intravenous) or via subcutaneous injection.
MabThera for maintenance treatment is given as a single infusion or subcutaneous injection every two to three months for a maximum of two years or earlier if your disease progresses.
The goal with maintenance treatment is to prevent relapse of your disease. If you achieved partial remission after induction treatment, MabThera maintenance treatment may help you reach complete remission.
Possible side effects of MabThera
Side effects can happen during or after you receive an infusion of MabThera. Some infusion reactions can be serious and life threatening.
All medicines can have side effects. Sometimes they are serious, most of the time they are not. It’s important to know what side effects may happen, and what symptoms to watch out for. You’ll find a list of possible side effect in the MabThera patient booklet by clicking here or MabThera Consumer Medicine Information by clicking here.
Always ask talk to your doctor if you have any questions or concerns.
Clinical trial data
The safety and efficacy of MabThera for the maintenance treatment of follicular lymphoma has been studied in clinical trials.
In one large clinical trial, it was shown that after 10 years of follow-up, 5 out of 10 patients that received MabThera maintenance therapy were free from disease progression (compared to 3.5 out of 10 patients who did not receive maintenance therapy).
The above numbers may not mean much to you now, but your doctor or nurse can explain their significance for you.
Keep in mind that everyone is different, and the response and benefit you may experience cannot be predicted.
How to access MabThera
MabThera is registered by Medsafe for induction and maintenance treatment but it is not funded by PHARMAC for maintenance treatment. This means you will have to pay for this medicine if you want to have maintenance therapy. Paying for treatment requires careful thought, but there are financial options that may help you fund private treatment. If you have health insurance, carefully check what’s covered — every health insurance provider has different rules and benefits that cover cancer treatment, surgery, tests and specialist appointments.
The MabThera Cost Share Access Programme
Roche New Zealand has a Cost Share Programme for MabThera which:
• Provides a number of cycles free during maintenance treatment.
• Spreads the costs over time, so not all of it has to be paid immediately
• Provides certainty as to the total cost you will pay for treatment as it is a set number of cycles over two years. (other costs such as doctor fees and administration payments will still apply).
Patients usually pay for each cycle as they go, meaning they only pay for treatment while they benefit from it.
Your specialist will be able to give you more information regarding the cost of your treatment and the criteria for enrolling in the MabThera Cost Share Programme.
What this means for you
It means there are other options for your particular type of cancer.
MabThera maintenance after MabThera induction can help to give you a longer remission – and a considerably reduced risk of relapse.
Innovative cancer treatments like MabThera for maintenance treatment are available in New Zealand but not funded by PHARMAC. These medicines are backed by high quality research and has been designed to deliver improved outcomes to give you more time and quality of life.
It’s important and empowering for you to understand all your options, and know you’re getting the treatment that gives you your best chance.
If you are considering treatment with MabThera, talk to your doctor about:
• How much the medicines will cost
• What benefits the medicines might give you
• What the risks or side effects may be
• Whether the Cost Share Programme is available to you.
All treatments need to be considered in line with your individual situation, and your healthcare provider will determine whether MabThera maintenance is the right treatment for you.
Ready to take the next step?
Making decisions about treatment options involves working through the advantages and disadvantages, so you can decide what may work best for you and your loved ones.
Because every situation is different, it’s important to speak to your medical team to find out if MabThera is right for you.
Talking to your doctor about MabThera
We’ve put together a discussion guide to help you begin a conversation with your doctor about MabThera. Print it off, take it along to your next appointment, and take notes in the spaces provided.
For further information about private treatment providers click here.
You can also talk to your current doctor about referral to a private doctor or treatment center.